Weidong Zheng

Dr. Weidong Zheng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
PLPeng Li
Peng Li
YZYu Zeng
Yu Zeng
YCYudan Chen
Yudan Chen
PHPeng Huang
Peng Huang
XCXinchun Chen
Xinchun Chen
WZWeidong Zheng
Weidong Zheng
Background: Breast cancer is the most commonly diagnosed cancer in women. Triple negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to the deficiency in drug-targetable receptors. LRP11-AS1, a newly identified oncogenic long noncoding RNA (lncRNA) was found to be significantly overexpressed in TNBC cells. The aim of this study is to investigate the malignant roles and the oncogenic mechanisms of LRP11-AS1 in TNBC. Methods: CCK-8, colony formation, transwell migration and transwell invasion assays were performed to study the functions of LRP11-AS1. Quantitative PCR and western blot were used to determine the gene expression. Bioinformatics analysis and dual-luciferase reporter assay were conducted to study lncRNA and miRNA interactions. Results: LRP11-AS1 was found to be significantly overexpressed in TNBC cells compared to the non-TNBC cells and normal mammary epithelial cells. Knockdown of LRP11-AS1 could inhibit the growth and metastasis of TNBC cells and regulate cell cycle. Mechanistically, LRP11-AS1 was found to act as a competing endogenous RNA (ceRNA) to sponge miR-149-3p. Silencing of LRP11-AS1 increased the expression of miR-149-3p and overexpression of miR-149-3p suppressed the expression of LRP11-AS1. Inhibition of miR-149-3p could reverse the anticancer effect of LRP11-AS1 deficiency in TNBC cells. Moreover, Neuropilin-2 (NRP2) was found to be the target of miR-149-3p. Rescue experiments revealed that NRP2 overexpression could rescue the anticancer effect of LRP11-AS1 deficiency in TNBC cells. Conclusion: LRP11-AS1 overexpressed in TNBC showed the oncogenic effects possibly by sponging miR-149-3p and regulating the miR-149-3p/NRP2 axis, which indicated LRP11-AS1 as a potential diagnostic biomarker and therapeutic target in TNBC.

11 March 2023 in Tuberculosis
Verified
Journal Article
Open access
CZChi Zhang
Chi Zhang
QOQi Ouyang
Qi Ouyang
XZXianyuan Zhou
Xianyuan Zhou
YHYingfeng Huang
Yingfeng Huang
YZYu Zeng
Yu Zeng
WZWeidong Zheng
Weidong Zheng
Multidrug-resistant tuberculosis (MDR-TB) has become a big threaten to global health. The current strategy for treatment of MDR-TB and extensive drug resistant tuberculosis (XDR-TB) is with low efficacy and high side effect. While new drug is fundamental for cure MDR-TB, repurposing the Food and Drug Administration (FDA)-approved drugs represents an alternative soluation with less cost. The activity of 8 tetracycline-class antibiotics against mycobacterium tuberculosis (M.tb) were determined by Minimum Inhibitory Concentration (MIC) in vitro. A transposon M.smeg libraries was generated by using the Harm phage and then used to isolate the conditional growth mutants in doxycycline containing plate. Eleven mutants were isolated and genomic DNAs were extracted using the cetyltrimethyl ammonium bromide (CTAB) method and analyzed by whole genome sequencing. We found that three of eight drugs efficiently inhibited mycobacteria growth under the peak plasma concentration in the human body. Further tests showed these three tetracycline analogs (demeclocycline, doxycycline and methacycline) had antimicrobial activity against seven clinical isolates, including MDR and XDR strains. Among them, Doxycycline had the lowest MICs in all mycobacteria strains tested in this study. By using a transposon library, we identify the insertion of transposon in two genes, porin and MshA, associatewith the resistant to doxycycline. Our findings show that tetracycline analogs such as doxycycline, has bactericidal activity against not only drug sensitive M.tb, but also clinical MDR and XDR strains, provided proof of concept to repurpose doxycycline to fight MDR-TB and XDR-TB. Further investigations are warranted to clarify the underlying mechanism and optimize the strategy in combination with other anti-TB drugs.

16 July 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
YZYu Zeng
Yu Zeng
LDLi Deng
Li Deng
XZXianyuan Zhou
Xianyuan Zhou
CZChi Zhang
Chi Zhang
ZHZhen Hu
Zhen Hu
WZWeidong Zheng
Weidong Zheng
This work is aimed to investigate the prevalence of tet(X4) in healthy individuals and patients and assess risk factors associated with tet(X4)-positive populations. A total of 662 patients and 120 healthy individuals from three municipal hospitals during August 2021 to September 2021 were selected to investigate the prevalence of tet(X4) in gut microbiota. A further case-control study was conducted to identify the risk factors associated with tet(X4)-positive populations. The tet(X4)-positive isolates were characterised by antimicrobial susceptibility testing, multilocus sequence typing (MLST), whole genome sequencing, and bioinformatics analyses. The prevalence of tet(X4)-positive Enterobacteriaceae in healthy individuals and patients (19.1%, 95% CI: 16.3%-21.8%) was substantially higher than previous studies in China (less than 1%). Patients ranging from 19 to 45 years of age had significantly higher odds of tet(X4)-positive bacterial colonization (OR = 2.545, 95% CI: 1.106-5.856). All tet(X4)-positive Enterobacteriaceae were resistant to tigecycline. In addition, tet(X4)-positive Escherichia coli were highly diverse, with CC10 belonging to the dominant clone. Genome analysis showed that tet(X4) was adjacent to ISVsa3 on the plasmids. Data from this study suggested that geographic region may partly explain the high prevalence of tet(X4)-positive Enterobacteriaceae in healthy individuals and patients. Young and middle-aged populations were associated with the colonization of tet(X4)-positive isolates.

13 December 2024 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
ZWZhongguang Wu
Zhongguang Wu
MYMengqiu Yu
Mengqiu Yu
YZYu Zeng
Yu Zeng
YHYingfeng Huang
Yingfeng Huang
WZWeidong Zheng
Weidong Zheng
Long noncoding RNAs (lncRNAs) are critical in tumorigenesis and show potential for tumor diagnosis and therapy. Enterotoxigenic Bacteroides fragilis (ETBF), known for producing enterotoxins, is implicated in human gut tumorigenesis, yet the underlying mechanisms are not fully elucidated. This study aims to clarify the molecular mechanisms by which lncRNAs contribute to ETBF-induced tumorigenesis, with a focus on LRP11-AS1’s role in modulating ETBF’s colorectal carcinogenesis. We found a marked increase in LRP11-AS1 expression in colorectal cancer (CRC) tissues compared to adjacent non-tumorous tissues. In vitro, CRC cells exposed to ETBF showed elevated LRP11-AS1 levels. Mechanistically, LRP11-AS1 was shown to enhance CDK4 expression by competitively binding to miR-149-3p. These results indicate that LRP11-AS1 may facilitate ETBF-related carcinogenesis in CRC and could serve as a therapeutic target and diagnostic biomarker for ETBF-associated CRC.

26 February 2026 in Medcomm
Verified
Journal Article
Open access
YSYali Song
Yali Song
YMYazhi Mo
Yazhi Mo
SCSi Chen
Si Chen
YCYuemei Chen
Yuemei Chen
CZChunying Zhang
Chunying Zhang
TZTingting Zeng
Tingting Zeng
Immune exhaustion is a state of sustained lymphocyte dysfunction that occurs following chronic antigenic stimulation and constitutes a shared hallmark of chronic infection and cancer. Beyond being a passive consequence of persistent antigen exposure, it actively drives tumor progression by fostering immunosuppressive microenvironments. Pathogens that evade immune detection to establish chronic infection can directly induce immune exhaustion through sustained inflammatory signaling, thereby crippling cytotoxic T cell‐mediated tumor surveillance. This impairment facilitates both de novo tumorigenesis and the aggressive evolution of pre‐existing malignancies. This comprehensive review delineates the mechanisms and characteristics of immune exhaustion within the contexts of chronic infection and cancer, as well as its impact on disease progression. Furthermore, we propose a chronic infection–exhaustion–tumor axis and analyze this pathway with reference to specific pathogens. Finally, we provide a critical appraisal of current strategies designed to reverse immune exhaustion and discuss their therapeutic potential and limitations within three defined contexts: chronic infection, cancer, and the interplay between chronic infection and tumor development. By integrating insights from virology and immuno‐oncology, this work proposes therapeutic strategies to disrupt the infection–exhaustion–tumor axis, offering a roadmap for precision oncology.